相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Katrin Mestermann et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph plus ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial
Sabina Chiaretti et al.
BLOOD (2019)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
BLOOD (2018)
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
Elias Jabbour et al.
LANCET HAEMATOLOGY (2018)
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
Giovanni Martinelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia
Rita Assi et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)
Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL
Virginie Naegele et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL
Philippe Rousselot et al.
BLOOD (2016)
Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study
Noriyoshi Iriyama et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells
Ryan Wong et al.
HAEMATOLOGICA (2013)
Selective Targeting of Distinct Active Site Nucleophiles by Irreversible Src-Family Kinase Inhibitors
Nathan N. Gushwa et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Philadelphia-Positive Acute Lymphoblastic Leukemia: Current Treatment Options
Theresa Liu-Dumlao et al.
CURRENT ONCOLOGY REPORTS (2012)
Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors
Juan Carlos Montero et al.
CLINICAL CANCER RESEARCH (2011)
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
Farhad Ravandi et al.
BLOOD (2010)
Lck is a key target of imatinib and dasatinib in T-cell activation
K. C. Lee et al.
LEUKEMIA (2010)
Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis
Neil P. Shah et al.
CANCER CELL (2008)
Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
Francois-Xavier Mahon et al.
CANCER RESEARCH (2008)
Profound inhibition of antigen-specific T-cell effector functions by dasatinib
Ralf Weichsel et al.
CLINICAL CANCER RESEARCH (2008)
The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro
Stephen Blake et al.
CLINICAL IMMUNOLOGY (2008)
Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens
Fei Fei et al.
EXPERIMENTAL HEMATOLOGY (2008)
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
Oliver Hantschel et al.
LEUKEMIA & LYMPHOMA (2008)
Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation
Andrew E. Schade et al.
BLOOD (2008)
分享论文
